Cellectar Biosciences (CLRB) Total Liabilities (2010 - 2026)
Cellectar Biosciences (CLRB) posted Total Liabilities of $5.1 million for Q4 2025, down 3.6% sequentially from $5.2 million in Q3 2025, and down 48.36% YoY from $9.8 million in Q4 2024.
Cellectar Biosciences (CLRB) Total Liabilities (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Total Liabilities for 16 years, with the latest figure at $5.1 million in Q4 2025.
- Quarterly Total Liabilities fell 48.36% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 48.36% YoY) and the FY2025 annual result came in at $5.1 million, down 48.36% from the prior year.
- Total Liabilities declined to $5.1 million in Q4 2025 per CLRB's latest filing, from $5.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $30.3 million in Q3 2023 and troughed at $3.4 million in Q3 2021.
- A 5-year average of $11.5 million and a median of $7.3 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 323.34% in 2023, then plunged 77.93% in 2025.
- Over 5 years, Total Liabilities stood at $4.2 million in 2021, then soared by 190.01% to $12.1 million in 2022, then soared by 114.46% to $25.9 million in 2023, then slumped by 62.1% to $9.8 million in 2024, then slumped by 48.36% to $5.1 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $5.1 million, $5.2 million, and $6.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | 6.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.77 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 6.41 Mn |
| Dec 31, 2024 | 9.80 Mn |
| Sep 30, 2024 | 20.75 Mn |
| Jun 30, 2024 | 15.62 Mn |
| Mar 31, 2024 | 29.03 Mn |
| Dec 31, 2023 | 25.85 Mn |
| Sep 30, 2023 | 30.35 Mn |
| Jun 30, 2023 | 13.52 Mn |
| Mar 31, 2023 | 12.09 Mn |
| Dec 31, 2022 | 12.05 Mn |
| Sep 30, 2022 | 7.17 Mn |
| Jun 30, 2022 | 6.60 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 4.16 Mn |
| Sep 30, 2021 | 3.37 Mn |
| Jun 30, 2021 | 3.75 Mn |